TVGN

Tevogen Bio Holdings Inc.
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$23.21M
P/E Ratio
EPS
$-6.04
Beta
0.22
52W High
$71.00
52W Low
$4.13
50-Day MA
$8.35
200-Day MA
$16.43
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. The company is headquartered in Warren, New Jersey.

Official WebsiteUSAFY End: June

Fundamentals

Revenue (TTM)0
Gross Profit (TTM)0
EBITDA$-21.00M
Operating Margin0.00%
Return on Equity0.00%
Return on Assets-294.40%
Revenue/Share (TTM)$0.00
Book Value$-4.47
Price-to-Book
Price-to-Sales (TTM)
EV/Revenue-
EV/EBITDA18.32
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$4.22M
Float$1.07M
% Insiders73.85%
% Institutions3.60%

Historical Volatility

HV 10-Day
160.04%
HV 20-Day
136.09%
HV 30-Day
146.23%
HV 60-Day
157.67%
HV Rank
86.1%

Volatility is currently expanding

Latest News

Tevogen Announces Formation of a Healthcare Services Initiative

William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the formation of its healthcare services initiative, a strategic business area intended to support the Company's evolution into a broader, revenue-generating healthcare enterprise.

GlobeNewsWire6/9/2026Neutral
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue.

GlobeNewsWire5/28/2026Neutral
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market.

GlobeNewsWire3/25/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026